Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 7–8
HOS-293198 · Präparat HOS-287836
7
hypokalaemia, neutropenia, and increased alanine amino transferase (ALT). Leucocytosis occurred
in 50% of patients with relapsed/refractory APL, as determined by haematology assessments.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage f36b2bdc7ad8fede5714e4ae60b40988f9cf54005c4f43d255323689fb0573eb · Zeichen 261–450 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-293199 · Präparat HOS-287836
Serious adverse reactions were common (1-10%) and not unexpected in the relapsed/refractory
population. Those serious adverse reactions attributed to arsenic trioxide included APL differentiation
syndrome (3), leucocytosis (3), prolonged QT interval (4, 1 with torsade de pointes), atrial
fibrillation/atrial flutter (1), hyperglycaemia (2) and a variety of serious adverse reactions related to
haemorrhage, infections, pain, diarrhoea, nausea.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage 58d84321d6d65d17082ab37aa00b4693982afc62243749696b420947953bb13d · Zeichen 452–896 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-293200 · Präparat HOS-287836
In general, treatment-emergent adverse events tended to decrease over time, in relapsed/refractory
APL patients perhaps accounted for by amelioration of the underlying disease process. Patients
tended to tolerate consolidation and maintenance treatment with less toxicity than in induction. This
is probably due to the confounding of adverse events by the uncontrolled disease process early on in
the treatment course and the myriad concomitant medicinal products required to control symptoms
and morbidity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage f44d498b03b4726954a257949862414ea2bdc8433a0d21562acc134be9f5802f · Zeichen 898–1405 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-293201 · Präparat HOS-287836
In a phase 3, multicentre, non-inferiority trial comparing all-trans-retinoic acid (ATRA) plus
chemotherapy with ATRA plus arsenic trioxide in newly diagnosed low-to-intermediate risk APL
patients (Study APL0406; see also section 5.1), serious adverse reactions including hepatic toxicity,
thrombocytopenia, neutropenia and QTc prolongation were observed in patients treated with arsenic
trioxide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage 0544e8a76eee8490a3385ce52dceafa947223faee6ca13e2a8b495f49341390d · Zeichen 1407–1804 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-293202 · Präparat HOS-287836
Tabulated list of adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage d51c90b617391dca447a849e03c6ddac1785fb6a36da5cf3e36f8f60e5aed8a9 · Zeichen 1806–1841 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-293203 · Präparat HOS-287836
The following undesirable effects have been reported in the APL0406 study in newly diagnosed
patients and in clinical trials and/or post-marketing experience in relapsed/refractory APL patients.
Undesirable effects are listed in table 2 below as MedDRA preferred term by system organ class and
frequencies observed during arsenic trioxide clinical trials in 52 patients with refractory/relapsed
APL. Frequencies are defined as: (very common ≥ 1/10), (common ≥ 1/100 to < 1/10), (uncommon ≥
1/1,000 to < 1/100), not known (cannot be estimated from available data).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage eabd217585eb031a03cf8757b1e63b0031567421c42ac5bec64dd2e0d30a07dc · Zeichen 1843–2406 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-293204 · Präparat HOS-287836
Within each frequency grouping, undesirable effects are presented in order of decreasing
seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage f0aea31bc762ee47d7c3019b5d8f9a5d214553f32e58645ef68cd2f716366f28 · Zeichen 2408–2509 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8–10
HOS-293205 · Präparat HOS-287836
All grades Grades ≥ 3
Infections and infestations
Herpes zoster Common Not known
Sepsis Not known Not known
Pneumonia Not known Not known
Blood and lymphatic system disorders
Febrile neutropenia Common Common
Leukocytosis Common Common
Neutropenia Common Common
Pancytopenia Common Common
Thrombocytopenia Common Common
Anaemia Common Not known
Leukopenia Not known Not known
Lymphopenia Not known Not known
Metabolism and nutrition disorders
Hyperglycaemia Very common Very common
Hypokalaemia Very common Very common
Hypomagnesaemia Very common Common
Hypernatraemia Common Common
8
All grades Grades ≥ 3
Ketoacidosis Common Common
Hypermagnesaemia Common Not known
Dehydration Not known Not known
Fluid retention Not known Not known
Psychiatric disorders
Confusional state Not known Not known
Nervous system disorders
Paraesthesia Very common Common
Dizziness Very common Not known
Headache Very common Not known
Convulsion Common Not known
Encephalopathy, Wernicke Not known Not known
encephalopathy
Eye disorders
Vision blurred Common Not known
Cardiac disorders
Tachycardia Very common Common
Pericardial effusion Common Common
Ventricular extrasystoles Common Not known
Cardiac failure Not known Not known
Ventricular tachycardia Not known Not known
Vascular disorders
Vasculitis Common Common
Hypotension Common Not known
Respiratory, thoracic and mediastinal disorders
Differentiation syndrome Very common Very common
Dyspnoea Very common Common
Hypoxia Common Common
Pleural effusion Common Common
Pleuritic pain Common Common
Pulmonary alveolar Common Common
haemorrhage
Pneumonitis Not known Not known
Gastrointestinal disorders
Diarrhoea Very common Common
Vomiting Very common Not known
Nausea Very common Not known
Abdominal pain Common Common
Skin and subcutaneous tissue disorders
Pruritus Very common Not known
Rash Very common Not known
Erythema Common Common
Face oedema Common Not known
Musculoskeletal and connective tissue disorders
Myalgia Very common Common
Arthralgia Common Common
Bone pain Common Common
Renal and urinary disorders
Renal failure Common Not known
General disorders and administration site conditions
Pyrexia Very common Common
Pain Very common Common
9
All grades Grades ≥ 3
Fatigue Very common Not known
Oedema Very common Not known
Chest pain Common Common
Chills Common Not known
Investigations
Alanine amino transferase Very common Common
increased
Aspartate amino transferase Very common Common
increased
Electrocardiogram QT Very common Common
prolonged
Hyperbilirubinaemia Common Common
Blood creatinine increased Common Not known
Weight increased Common Not known
Gamma-glutamyltransferase Not known* Not known*
increased*
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage 739774918b42448d6637af446b78764f8ba077d7bd2b815dcf4f88896d856bd4 · Zeichen 2564–7905 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-293206 · Präparat HOS-287836
*In the CALGB study C9710, 2 cases of grade ≥3 increased GGT were reported out of the 200
patients who received arsenic trioxide consolidation cycles (cycle 1 and cycle 2) versus none in
the control arm.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage e0620759b8e0adb946999651acb666d051128b1d2f59d0072e8461ff5c49f761 · Zeichen 7907–8110 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-293207 · Präparat HOS-287836
Description of selected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage f66db2a8100a521c1dea72ff90e696fa3846f9d5fcd6cf8e5e03ce5d71bde4a7 · Zeichen 8112–8153 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-293208 · Präparat HOS-287836
Differentiation syndrome
During arsenic trioxide treatment, 14 of the 52 patients in the APL studies in the relapsed setting had
one or more symptoms of APL differentiation syndrome, characterised by fever, dyspnoea, weight
gain, pulmonary infiltrates and pleural or pericardial effusions, with or without leucocytosis (see
section 4.4). Twenty-seven patients had leucocytosis (WBC 10 x 103/l) during induction, 4 of
whom had values above 100,000/l. Baseline white blood cell (WBC) counts did not correlate with
development of leucocytosis on study, and WBC counts during consolidation therapy were not as
high as during induction. In these studies, leucocytosis was not treated with chemotherapeutic
medicinal products.
Medicinal products that are used to lower the white blood cell count often exacerbate the toxicities
associated with leucocytosis, and no standard approach has proven effective. One patient treated
under a compassionate use program died from cerebral infarct due to leucocytosis, following
treatment with chemotherapeutic medicinal products to lower WBC count. Observation is the
recommended approach with intervention only in selected cases.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage 6993d9b243ce4923e5ce719d9cf1bfeb1ce79cf0dae90bf517788a4a48cec4b8 · Zeichen 8155–9322 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-293209 · Präparat HOS-287836
Mortality in the pivotal studies in the relapsed setting from disseminated intravascular coagulation
(DIC) associated haemorrhage was very common (> 10%), which is consistent with the early
mortality reported in the literature.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage 4534232afa8b7cfb93b0b07fbf4dce896e825d5095012a042be53519126be0f0 · Zeichen 9324–9551 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-293210 · Präparat HOS-287836
In newly diagnosed patients with low to intermediate risk APL, differentiation syndrome was
observed in 19 % including 5 severe cases.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage 0a8ff3d93bd48522094d22f19a1ebf985635ceaedea94292541a341d09df99c3 · Zeichen 9553–9687 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-293211 · Präparat HOS-287836
In post marketing experience, a differentiation syndrome, like retinoic acid syndrome, has also been
reported for the treatment of malignancies other than APL with arsenic trioxide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage 728db79eaa359e15ebf4ea23eabc6f452bc1ab27830b64f65e0929aefbce5ad9 · Zeichen 9689–9870 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-293212 · Präparat HOS-287836
QT interval prolongation
Arsenic trioxide can cause QT interval prolongation (see section 4.4). QT prolongation can lead to a
torsade de pointes-type ventricular arrhythmia, which can be fatal. The risk of torsade de pointes is
related to the extent of QT prolongation, concomitant administration of QT prolonging medicinal
products, a history of torsade de pointes, pre-existing QT interval prolongation, congestive heart
failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalaemia
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage a5366304f2f5d2c73f3fa2afb4a9dfe9bafd9ba133fb163e09be80491a4aeac8 · Zeichen 9872–10398 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10–11
HOS-293213 · Präparat HOS-287836
10
or hypomagnesaemia. One patient (receiving multiple, concomitant medicinal products, including
amphotericin B) had asymptomatic torsade de pointes during induction therapy for relapsed APL
with arsenic trioxide. She went onto consolidation without further evidence of QT prolongation.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage 4ad4cb22659090d89bcd9a64194e6f107699b095ea35e9961363badd2fb421d1 · Zeichen 10451–10739 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-293214 · Präparat HOS-287836
In newly diagnosed patients, with low to intermediate risk APL, QTc prolongation was observed in
15.6 %. In one patient induction treatment was terminated because of severe prolongation of the QTc
interval and electrolyte abnormalities on day 3.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage c75e14573a428b2ad5430e6a8fee3f00d341b215f8c10424a8a88322313b9d5b · Zeichen 10741–10986 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-293215 · Präparat HOS-287836
Peripheral neuropathy
Peripheral neuropathy, characterised by paraesthesia/dysaesthisia, is a common and well known
effect of environmental arsenic. Only 2 relapsed/refractory APL patients discontinued treatment early
due to this adverse event and one went on to receive additional arsenic trioxide on a subsequent
protocol. Forty-four per cent of relapsed/refractory APL patients experienced symptoms that could be
associated with neuropathy; most were mild to moderate and were reversible upon cessation of
treatment with arsenic trioxide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage bf61183cb74296b68ff1ec8327320624a30f0b605e8bba5d953320d3cb27cc75 · Zeichen 10988–11529 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-293216 · Präparat HOS-287836
Hepatotoxicity (grade 3-4)
In newly diagnosed patients with low to intermediate risk APL 63.2 % developed grade 3 or 4
hepatic toxic effects during induction or consolidation treatment with arsenic trioxide in combination
with ATRA. However, toxic effects resolved with temporary discontinuation of either arsenic
trioxide, ATRA or both (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage 90bbf2af8bc8a4f0b88f5bfcf91ff22b58cb38dee4494599318372fe4d59a152 · Zeichen 11531–11886 im Abschnitt
Nebenwirkungen · Arsenic trioxide Accord
Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-293217 · Präparat HOS-287836
Haematological and gastrointestinal toxicity
In newly diagnosed patients with low to intermediate risk APL, gastrointestinal toxicity, grade 3-4
neutropenia and grade 3 or 4 thrombocytopenia occurred, however these were 2.2 times less frequent
in patients treated with arsenic trioxide in combination with ATRA compared to patients treated with
ATRA + chemotherapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T10:03:00Z · SHA-256 7e12af9ddb3c21e71d6bde468f903ac44f6080f4f47633520887009a5dad2924 · Passage 7b489b56521b4acc2f3ec7c24c59c048702b5442a560d6841fabb006a90ef90c · Zeichen 11888–12253 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.